AbbVie vs BBVA: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. BBVA was founded in 1857 by Bilbao Board of Trade and is led by Onur Genç.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
BBVA
Bilbao Board of Trade
No individual is recorded as the founder of BBVA's oldest institution. Banco de Bilbao was created in 1857 after the Bilbao Board of Trade, the body representing the port city's merchants, promoted a bank that could issue banknotes and discount commercial bill…
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
BBVA
- Pedro Luis Uriarte1999–2001
Chief Executive Officer
Chief executive and vice chairman of BBV from September 1994 and of the merged BBVA until he retired at the end of 2001.
Source - Francisco Gonzalez2000–2018
Executive Chairman
Chaired Argentaria before its 1999 merger with BBV and then BBVA until December 2018, 22 years at the head of the group in total. He drove the bank's technology rebuild and the 2007 purchase of Compass Bancshares in the United States.
Source - Jose Ignacio Goirigolzarri2001–2009
Chief Executive Officer
Chief executive of BBVA from 2001 to 2009, the period that covered the USD4.1 billion buyout of the rest of BBVA Bancomer in 2004 and the USD9.6 billion purchase of Compass Bancshares in 2007. He later chaired Bankia and CaixaBank.
Source - Angel Cano2009–2015
Chief Executive Officer
Appointed chief executive in September 2009, replacing Jose Ignacio Goirigolzarri.
Source - Carlos Torres Vila2015–2018
Chief Executive Officer
Chief executive from May 2015 until December 31, 2018, when he became executive chairman and Onur Genc took over as CEO. He had joined BBVA in 2008 to run strategy and corporate development and led digital banking from 2014.
Source - Onur Genc2018–present
Chief Executive Officer
Took over as CEO on December 31, 2018, the day Carlos Torres Vila became executive chairman.
Source
Timeline: AbbVie and BBVA side by side
1857BBVA
Banco de Bilbao is created
Bilbao's Board of Trade promotes the creation of Banco de Bilbao as a bank of issue and discount for the city's merchants. It is the oldest institution in BBVA's corporate line.
1901BBVA
Banco de Vizcaya is founded
Banco de Vizcaya is founded in Bilbao and grows alongside Banco de Bilbao as the second large Basque bank, financing regional industry.
1988BBVA
Banco de Bilbao and Banco de Vizcaya merge
The two Basque rivals merge to form Banco Bilbao Vizcaya (BBV), one of the largest banks in Spain ahead of the European single market.
1999BBVA
BBV merges with Argentaria to create BBVA
BBV merges with Argentaria, the group Spain had assembled from state-owned lenders such as Banco Exterior, Banco Hipotecario and Caja Postal, forming Banco Bilbao Vizcaya Argentaria.
2000BBVA
BBVA takes control of Bancomer in Mexico
BBVA capitalizes Bancomer with USD1.4 billion and merges it with BBV-Probursa to create Grupo Financiero BBVA Bancomer, the largest bank in Mexico.
2004BBVA
BBVA bids for the rest of BBVA Bancomer
BBVA offers USD4.1 billion in cash for the roughly 41 percent of BBVA Bancomer held by minority investors, ending with about 99 percent of the Mexican group.
2007BBVA
Compass Bancshares purchase builds a US franchise
BBVA buys Compass Bancshares of Birmingham, Alabama for USD9.6 billion, creating a Sunbelt retail bank that later traded as BBVA Compass and BBVA USA.
2010BBVA
BBVA agrees to buy 24.9 percent of Garanti
BBVA agrees to pay ~$4.74 billion (EUR4.195 billion), about USD5.84 billion, for 24.9 percent of Turkiye Garanti Bankasi, funded with a rights issue of about $5.65 billion (EUR5 billion).
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2014BBVA
BBVA wins the auction for Catalunya Banc
BBVA bids ~$1.34 billion (EUR1.187 billion) for Catalunya Banc, with 1.5 million customers and ~$71.2 billion (EUR63 billion) of assets, in the auction run by Spain's bank restructuring fund. The deal closed in 2015.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2018BBVA
Onur Genc is named CEO
BBVA's board designates Onur Genc as chief executive from December 31, 2018, the date Carlos Torres Vila replaces Francisco Gonzalez as executive chairman.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2019BBVA
BBVA unifies its brand worldwide
The group drops local names such as BBVA Bancomer, BBVA Francés, BBVA Continental and BBVA Compass and operates as BBVA in every market.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2021BBVA
BBVA closes the transfer of BBVA USA to PNC
BBVA completes the transfer of BBVA USA Bancshares to PNC Financial Services on June 1, 2021, receiving about USD11.5 billion, equivalent to ~$10.8 billion (EUR9.6 billion), in cash.
2022BBVA
Tender offer lifts the Garanti stake to 85.97 percent
A tender offer at 15 Turkish lira per share closes in May 2022 and raises BBVA's holding in Garanti BBVA to 85.97 percent.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025BBVA
The offer for Banco Sabadell lapses
Shareholders representing 25.47 percent of Sabadell's voting rights accept BBVA's all-share offer, short of the minimum BBVA required, and the bid lapses on October 16, 2025.
2025BBVA
Record net attributable profit of ~$11.9B (EUR10.511B)
BBVA reports gross income of ~$41.7B (EUR36.931B) and net attributable profit of ~$11.9B (EUR10.511B) for 2025, with ROTE of 19.3 percent and an efficiency ratio of 38.8 percent.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
2026BBVA
BBVA is ordered to stand trial in the Villarejo case
Spain's National Court orders BBVA, former chairman Francisco Gonzalez and 14 other defendants to stand trial over work commissioned from former police commissioner Jose Manuel Villarejo between 2004 and 2016.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
BBVA
- Turkiye Garanti Bankasi tender offer (Turkey)2022Undisclosed
- Catalunya Banc (Spain)2014Undisclosed
- Turkiye Garanti Bankasi 24.9 percent stake (Turkey)2010$5.8B
- Compass Bancshares (United States)2007$9.6B
- BBVA Bancomer minority shares (Mexico)2004$4.1B
- Grupo Financiero Bancomer (Mexico)2000$1.4B
Questions about AbbVie vs BBVA
Who is the CEO of AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A.?
AbbVie Inc. is led by Robert A. Michael and Banco Bilbao Vizcaya Argentaria, S.A. is led by Onur Genç. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Banco Bilbao Vizcaya Argentaria, S.A.?
Banco Bilbao Vizcaya Argentaria, S.A. was founded in 1857 — 156 years before AbbVie Inc., which was founded in 2013. Banco Bilbao Vizcaya Argentaria, S.A.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Banco Bilbao Vizcaya Argentaria, S.A.?
AbbVie Inc. employs approximately 57,000 people, while Banco Bilbao Vizcaya Argentaria, S.A. employs approximately 127,174. Banco Bilbao Vizcaya Argentaria, S.A. has the larger workforce at 127,174 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A. headquartered?
AbbVie Inc. is headquartered in United States and Banco Bilbao Vizcaya Argentaria, S.A. is headquartered in Spain. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AbbVie Inc. and Banco Bilbao Vizcaya Argentaria, S.A.?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Banco Bilbao Vizcaya Argentaria, S.A. was founded by Bilbao Board of Trade.
Which company has a longer operating history — AbbVie Inc. or Banco Bilbao Vizcaya Argentaria, S.A.?
Banco Bilbao Vizcaya Argentaria, S.A. has been operating for approximately 169 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs BBVA overview